Illumina recently announced its cancer panel. BRCA1 and BRCA2 are, of course, left out due to patents on these crucial genes involved in breast and ovarian cancers. Cancer panels provided by other institutions will probably follow suit. We are at a crucial juncture before a potential Supreme Court ruling that could seal the fate of our genes. Is there anything that we as a community can do to make a difference?
Somewhat off the main point, but related . . . If these genes can't be included in a targeted-capture panel, can you target the reverse-complement sequence? The patent is on the gene, and the gene is on just one of the two strands - so why not just go after the other strand? Probably wouldn't fly, but I just thought I would throw that out there.
I would like to do something, rather than just sit around and see what happens, but not quite sure what best to do. Any ideas?
thanks,
Justin
Somewhat off the main point, but related . . . If these genes can't be included in a targeted-capture panel, can you target the reverse-complement sequence? The patent is on the gene, and the gene is on just one of the two strands - so why not just go after the other strand? Probably wouldn't fly, but I just thought I would throw that out there.
I would like to do something, rather than just sit around and see what happens, but not quite sure what best to do. Any ideas?
thanks,
Justin
Comment